Mayo Clinic Laboratories > Neurology > Autoimmune > Neuropathies

AUTOIMMUNE Peripheral Neuropathy

Biomarker evaluations to guide treatment

Peripheral autoimmune neuropathies have a variety of causes that have either axonal or demyelinating associations. While these conditions have overlapping features, treatment response differs depending on the underlying cause. Pinpointing disease etiology through biomarker evaluation enables valuable insights on treatment response. Our autoimmune neuropathy test offerings evaluate for specific antibodies linked to the illness. Using electrophysiology test results as a determining factor for which test to order, our expert-backed evaluations provide accurate results to confirm diagnosis and set patients on the best treatment path.

Axonal neuropathies Axonal neuropathies
Axonal neuropathies

Because of the overlap of clinical symptoms or autoimmune neuropathies, we recommend a panel-based approach rather than individual antibody testing. Order these tests when nerve conduction velocity studies reveal lower amplitudes with relatively preserved conduction velocity.

Demyelinating neuropathies Demyelinating neuropathies
Demyelinating neuropathies

Driven by ongoing research into the presence of antibody biomarkers in patients with immune-mediated demyelinating neuropathy, Mayo Clinic Laboratories has developed several unique, highly accurate assays that use pioneering methods to identify specific biomarkers associated with the harmful immune response. Order these tests when nerve conduction studies show prolonged distal latency or marked slowing of conduction velocities.

Ganglioside-associated neuropathies Ganglioside-associated neuropathies
Ganglioside-associated neuropathies

Our clinically validated ganglioside-related neuropathy evaluation provides increased specificity for detecting several ganglioside antibodies associated with treatable autoimmune conditions.

News and updates

The latest

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Learn more
Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D.

Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.

Autoimmune Axonal Evaluation

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.

MAG Antibody Testing [Test in Focus]

John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.